Prelude Capital Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Prelude Capital Management’s Portfolio SIOX Stock Details SIOX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-34,000	Closed	-$74K	–	2362
2021 Q3	$74K	Hold	34,000	–	–	﹤0.01%	1527
2021 Q2	$93K	Hold	34,000	–	–	﹤0.01%	1487
2021 Q1	$89K	Hold	34,000	–	–	﹤0.01%	1444
2020 Q4	$95K	Hold	34,000	–	–	﹤0.01%	1181
2020 Q3	$157K	Buy	34,000 +16,100	+90%	+$53.1K	0.01%	764
2020 Q2	$50K	Buy	+17,900	New	+$57.4K	﹤0.01%	1161
2017 Q4	–	Sell	-12	Closed	-$1K	–	1813
2017 Q3	$1K	Sell	12 -2,166	-99%	-$365K	﹤0.01%	1573
2017 Q2	$404K	Hold	2,178	–	–	0.04%	374
2017 Q1	$260K	Buy	2,178 +1,363	+167%	+$143K	0.02%	476
2016 Q4	$81K	Buy	+815	New	+$85.8K	0.01%	893

Other funds holding SIOX

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

CIA

Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Prelude Capital Management's SIOX Position: Q4 2021 in Review

Prelude Capital Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q4 2021, closing a stake of 34,000 shares — an estimated $74K sold.

Prelude Capital Management first reported a position in SIOX in Q4 2016 and held it in 10 quarters. The position peaked at $404K in Q2 2017. 48 funds tracked by Wall St. Rank hold SIOX as of Q4 2021.

Prelude Capital Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Prelude Capital Management sold 34,000 Sio Gene Therapies Inc. Common Stock shares in Q4 2021, an estimated $74K.
Prelude Capital Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q4 2016 and held it in 10 quarters.
Prelude Capital Management's Sio Gene Therapies Inc. Common Stock position peaked at $404K in Q2 2017.
48 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q4 2021.

Based on Prelude Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.